Health and Healthcare
Why Pfizer Is Tripping Over Itself With Earnings
Published:
Last Updated:
Pfizer Inc. (NYSE: PFE) reported its most recent quarterly results before the markets opened on Tuesday. The pharmaceutical giant said that it had $0.69 in earnings per share (EPS) and $13.3 billion in revenue, compared with consensus estimates of $0.75 in EPS and $13.53 billion in revenue. In the same period of last year, it posted EPS of $0.67 on revenue of $13.17 billion.
During the most recent quarter, the company repurchased $1.1 billion of common stock, as well as $9.0 billion of common stock year to date. Pfizer now has its sights set on repurchasing a total of $12 billion worth of common stock in 2018.
In terms of its segments, the company reported as follows:
- Innovative Health (IH) revenues increased 5% operationally to $8.47 billion, primarily driven by continued growth from key brands including: Eliquis (up 36%), Ibrance (up 12%), Prevnar (up 12%), Xtandi (up 26%).
- Essential Health (EH) revenues declined 4% operationally to $4.83 billion, negatively impacted primarily by a 14% operational decline in the Legacy Established Products (LEP) portfolio in developed markets and a 17% operational decline in the Peri-LOE Products portfolio.
Looking ahead to the 2018 full year, the company expects to see EPS in the range of $2.98 to $3.02 and revenues between $53.0 billion and $53.7 billion. Consensus estimates call for $2.99 in EPS and $54.15 billion in revenue for the year.
Ian Read, board chair and chief executive, commented:
We reported solid third-quarter 2018 financial results, with total company revenues up 2% operationally, driven by the continued growth of key brands such as Eliquis, Ibrance, Prevnar 13, Xeljanz and Xtandi, as well as biosimilars and emerging markets. The performance of these growth drivers was partially offset by product losses of exclusivity, a decline in Legacy Established Products in developed markets and ongoing legacy Hospira sterile injectable supply shortages.
Shares of Pfizer closed Monday at 43.23, with a consensus analyst price target of $43.11. The stock has a 52-week range of $33.20 to $45.81. Following the announcement, shares were down 3.5% at $41.70 in early trading indications Tuesday.
The Average American Is Losing Their Savings Every Day (Sponsor)
If you’re like many Americans and keep your money ‘safe’ in a checking or savings account, think again. The average yield on a savings account is a paltry .4% today, and inflation is much higher. Checking accounts are even worse.
Every day you don’t move to a high-yield savings account that beats inflation, you lose more and more value.
But there is good news. To win qualified customers, some accounts are paying 9-10x this national average. That’s an incredible way to keep your money safe, and get paid at the same time. Our top pick for high yield savings accounts includes other one time cash bonuses, and is FDIC insured.
Click here to see how much more you could be earning on your savings today. It takes just a few minutes and your money could be working for you.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
